NRXP Stock Summary and Trading Ideas (NRX Pharmaceuticals | NASDAQ:NRXP)

NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.

NRX Pharmaceuticals trades on the NASDAQ stock market under the symbol NRXP.

As of February 9, 2026, NRXP stock price climbed to $1.99 with 406,954 million shares trading.

NRXP has a beta of 2.05, meaning it tends to be more sensitive to market movements. NRXP has a correlation of 0.23 to the broad based SPY ETF.

NRXP has a market cap of $58.91 million. This is considered a Micro Cap stock.

Last quarter NRX Pharmaceuticals reported $242,000 in Revenue and -$.27 earnings per share. This fell short of revenue expectation by $-11 million and missed earnings estimates by -$.22.

In the last 3 years, NRXP traded as high as $12.80 and as low as $1.10.

The top ETF exchange traded funds that NRXP belongs to (by Net Assets): VTI, PSIL, VXF, IWC.

NRXP has underperformed the market in the last year with a price return of -37.4% while the SPY ETF gained +15.7%. NRXP has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -25.5% and -8.3%, respectively, while the SPY returned +3.8% and +0.7%, respectively.

NRXP support price is $1.80 and resistance is $2.02 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that NRXP shares will trade within this expected range on the day.